Article ; Online: Door to Intravenous Tissue Plasminogen Activator Time and Hospital Length of Stay in Acute Ischemic Stroke Patients, Georgia, 2007-2013.
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
2016 Volume 25, Issue 4, Page(s) 866–871
Abstract: Background: Ischemic stroke patients benefit most from intravenous thrombolysis when they receive the treatment as quickly as possible after symptom onset. Hospitals participating in the Georgia Coverdell Acute Stroke Registry reduced the time from ... ...
Abstract | Background: Ischemic stroke patients benefit most from intravenous thrombolysis when they receive the treatment as quickly as possible after symptom onset. Hospitals participating in the Georgia Coverdell Acute Stroke Registry reduced the time from patient arrival to administration of intravenous tissue plasminogen activator. This study evaluates the benefit of reducing door-to-treatment (DTT) time as measured by hospital length of stay (LOS). Methods: Data from 3154 ischemic stroke patients treated with intravenous thrombolysis from 2007 to 2013 were analyzed. The impact of door-to-treatment time on patients' length of hospital stay, discharge disposition, ambulatory status at discharge, and bleeding complications was assessed, controlling for patient-, hospital- and event-related characteristics. Results: Patients who received intravenous thrombolysis within 30 minutes of hospital arrival had a 19% shorter (95% confidence interval [CI]: 2%-32%, P value = .04) hospital LOS than those treated for more than 120 minutes after arrival. Patients treated within 60 minutes of arrival were 27% more likely (odds ratio = 1.28, 95% CI: 1.06-1.56, P = .01) to have a better discharge disposition than patients treated after 60 minutes of arrival while having a similar rate of bleeding complications. Conclusions: Shortening the door-to-treatment time is associated with a decrease in patient LOS and better patient outcomes. Hospitals should be encouraged to measure, monitor, and reduce DTT time progressively for a better patient outcome. |
---|---|
MeSH term(s) | Aged ; Brain Ischemia/complications ; Female ; Fibrinolytic Agents/therapeutic use ; Georgia/epidemiology ; Humans ; Length of Stay/statistics & numerical data ; Male ; Middle Aged ; Multivariate Analysis ; Retrospective Studies ; Stroke/drug therapy ; Stroke/epidemiology ; Stroke/etiology ; Time-to-Treatment/statistics & numerical data ; Tissue Plasminogen Activator/therapeutic use |
Chemical Substances | Fibrinolytic Agents ; Tissue Plasminogen Activator (EC 3.4.21.68) |
Language | English |
Publishing date | 2016-04 |
Publishing country | United States |
Document type | Journal Article ; Research Support, U.S. Gov't, P.H.S. |
ZDB-ID | 1131675-5 |
ISSN | 1532-8511 ; 1052-3057 |
ISSN (online) | 1532-8511 |
ISSN | 1052-3057 |
DOI | 10.1016/j.jstrokecerebrovasdis.2015.12.025 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3519: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.